Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients
Status:
Withdrawn
Trial end date:
2018-01-15
Target enrollment:
Participant gender:
Summary
The study is prospectively initiated to: (1) evaluate the alterations in platelet function to
aspirin therapy and the prevalence of aspirin resistance in patients with chronic kidney
disease undergoing hemodialysis, and (2) compare the incidence of vascular events (myocardial
infarction, cardiac death, stroke, vascular access thrombosis, or revascularization
procedure) and the safety profile among placebo-treated, aspirin-resistant and
aspirin-sensitive patients.
Phase:
Phase 4
Details
Lead Sponsor:
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation